Macrogen, Inc. (KOSDAQ:038290)
South Korea
· Delayed Price · Currency is KRW 16,930
+60 (0.36%)
At close: Dec 5, 2025
Macrogen Revenue
Macrogen had revenue of 49.06B KRW in the quarter ending September 30, 2025, with 48.67% growth. This brings the company's revenue in the last twelve months to 179.98B, up 36.63% year-over-year. In the year 2024, Macrogen had annual revenue of 135.78B with 2.24% growth.
Revenue (ttm)
179.98B
Revenue Growth
+36.63%
P/S Ratio
1.02
Revenue / Employee
378.91M
Employees
500
Market Cap
183.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 135.78B | 2.97B | 2.24% |
| Dec 31, 2023 | 132.80B | -5.81B | -4.19% |
| Dec 31, 2022 | 138.62B | 9.44B | 7.31% |
| Dec 31, 2021 | 129.17B | 16.57B | 14.72% |
| Dec 31, 2020 | 112.60B | 9.79B | 9.52% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |